The pharmaceutical supply chains faced several challenges during the COVID-19 pandemic. Demand became uncertain as antiviral use rose but other chronic conditions went untreated. Limited workforces due to social distancing and travel restrictions affected sourcing and distribution. Manufacturing faced shortages of active pharmaceutical ingredients and delays in new product development. To prepare for continued uncertainty in 2021, pharmaceutical supply chains should diversify suppliers, prioritize worker safety, implement technologies like blockchain for transparency, and explore creative transport solutions to maintain resilience and flexibility.